Iadademstat联合阿扎胞苷治疗新诊断急性髓系白血病(ALICE):一项开放标签2a期剂量探索研究
ALICE研究为开放标签2a期剂量探索研究,在西班牙6家医院纳入36例不适合强化化疗的新诊断急性髓系白血病患者。推荐2期剂量为iadademstat每日90μg/m2联合阿扎胞苷。疗效分析集27例中22例(82%;95%CI 62-94)达客观缓解,14例(52%)达完全缓解或完全缓解伴血液学不完全恢复。
要点
- 推荐2期剂量为iadademstat每日90μg/m2联合阿扎胞苷75mg/m2皮下注射。
- 疗效分析集客观缓解率为82%(22/27;95%CI 62-94),完全缓解或完全缓解伴血液学不完全恢复为52%(14/27)。
- 最常见治疗相关不良事件为血小板减少(69%)、中性粒细胞减少(61%)和贫血(42%),均为3-4级。
核心结论
- Iadademstat联合阿扎胞苷具有可控的安全性,并在新诊断急性髓系白血病(包括高危预后因素患者)中显示出有前景的缓解。
研究设计与样本
- 开放标签、2a期剂量探索ALICE研究,在西班牙6家医院纳入36例年龄≥18岁、不适合强化化疗、ECOG体能状态0-2分的新诊断急性髓系白血病患者。
- 剂量递增部分起始剂量为iadademstat每日90μg/m2口服(可降至每日60μg/m2,可升至每日140μg/m2),每周用药5天停2天,联合阿扎胞苷75mg/m2皮下注射,每28天用药7天。
- 主要目标为安全性和确定推荐2期剂量;次要目标包括疗效分析集的缓解率。
主要发现
- 2018年11月12日至2021年9月30日纳入36例患者,中位年龄76岁(IQR 74-79),男性18例(50%)、女性18例(50%),全部为中间危或不良危急性髓系白血病。
- 中位随访22个月(IQR 16-31)。
- 最常见(≥10%)治疗相关不良事件为血小板减少25例(69%)和中性粒细胞减少22例(61%)(均为3-4级)及贫血15例(42%;其中10例[28%]为3-4级)。
- 3例发生治疗相关严重不良事件:1例致死性5级颅内出血、1例3级分化综合征、1例3级发热性中性粒细胞减少。
- 基于安全性、药代动力学、药效动力学和疗效数据,推荐2期剂量为iadademstat每日90μg/m2联合阿扎胞苷。
关键数值与推荐
- 疗效分析集27例中22例(82%;95%CI 62-94)达客观缓解。
- 疗效分析集27例中14例(52%)达完全缓解或完全缓解伴血液学不完全恢复;其中11例可评估可测量残留病灶者中10例达阴性。
- 安全性分析集36例中22例(61%)达客观缓解。
临床怎么用
- 作者结论认为该联合方案安全性可控并在新诊断急性髓系白血病中显示出有前景的缓解,包括高危预后因素患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iadademstat is a potent, selective, oral inhibitor of both the enzymatic and scaffolding activities of the transcriptional repressor lysine-specific demethylase 1 (LSD1; also known as KDM1A) that showed promising early activity and safety in a phase 1 trial and strong preclinical synergy with azacitidine in acute myeloid leukaemia cell lines. Therefore, we aimed to investigate the combination of iadademstat and azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia. METHODS: The open-label, phase 2a, dose-finding ALICE study was conducted at six hospitals in Spain and enrolled patients aged 18 years or older with newly diagnosed acute myeloid leukaemia not eligible for intensive chemotherapy and an ECOG performance status of 0-2. In the dose escalation portion of the trial, patients received a starting dose of iadademstat at 90 μg/m2 per day (with de-escalation to 60 μg/m2 per day and escalation up to 140 μg/m2 per day) orally, for 5 days on, 2 days off weekly, with azacitidine 75 mg/m2 subcutaneously, for seven of 28 days. The primary objectives were safety (analysed in the safety analysis set; all patients who received at least one dose of study treatment) and establishing the recommended phase 2 dose; secondary objectives included response rates in the efficacy analysis set (all patients who had at least one efficacy assessment). This study is registered on EudraCT (EudraCT 2018-000482-36) and has been completed. FINDINGS: Between Nov 12, 2018, and Sept 30, 2021, 36 patients with newly diagnosed acute myeloid leukaemia were enrolled; the median age was 76 (IQR 74-79) years, all patients were White, 18 (50%) were male, and 18 (50%) were female, and all had intermediate-risk or adverse-risk acute myeloid leukaemia. The median follow-up was 22 (IQR 16-31) months. The most frequent (≥10%) adverse events considered to be related to treatment were decreases in platelet (25 [69%]) and neutrophil (22 [61%]) counts (all grade 3-4) and anaemia (15 [42%]; of which ten [28%] were grade 3-4). Three patients had treatment-related serious adverse events (one fatal grade 5 intracranial haemorrhage, one grade 3 differentiation syndrome, and one grade 3 febrile neutropenia). Based on safety, pharmacokinetic and pharmacodynamic data, and efficacy, the recommended phase 2 dose of iadademstat was 90 μg/m2 per day with azacitidine. 22 (82%; 95% CI 62-94) of 27 patients in the efficacy analysis set had an objective response. 14 (52%) of 27 patients had complete remission or complete remission with incomplete haematological recovery; of these, ten of 11 evaluable for measurable residual disease achieved negativity. In the safety analysis set, 22 (61%) of 36 patients had an objective response. INTERPRETATION: The combination of iadademstat and azacitidine has a manageable safety profile and shows promising responses in patients with newly diagnosed acute myeloid leukaemia, including those with high-risk prognostic factors. FUNDING: Oryzon Genomics and Spain's Ministerio de Ciencia, Innovacion y Universidades (MICIU)-Agencia Estatal de Investigacion (AEI).
引用
- Salamero O, Molero A, Pérez-Simón JA, et al. Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study. Lancet Haematol. 2024. PMID: 38824932. doi:10.1016/S2352-3026(24)00132-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。